A 3-year-old child with SMA type 1 received Zolgensma (onasemnogene abeparvovec) as an infant with excellent motor outcomes. Now approaching school age, the treating neurologist is concerned about potential loss of therapeutic efficacy. What is the most likely mechanism for declining transgene expression over time in this patient?